🎧 What Investors Get Wrong About Hims & Hers, Ep. 2 with Paul Cerro

The episode opens with a comparison between Hims & Hers (HEMS) and industry giant Novo Nordisk. While Novo Nordisk enjoys gross margins above 80 percent by owning its API production and full supply chain, HEMS operates as a compounder that purchases finished drugs from manufacturers. Because it does not control the manufacturing cost base, HEMS can never achieve higher gross margins than the producers themselves. This structural limitation frames the conversation about why HEMS’s margin trajectory is inherently capped, regardless of pricing tactics or scale. Consequently, analysts often benchmark HEMS against pure‑play manufacturers rather than direct‑to‑consumer peers.

The hosts then trace the recent margin decline, noting a drop from 73.5 % to 71.9 % in the latest quarter. The primary driver is a shift in product mix toward higher‑average‑order‑value (AOV) items with lower margin contributions. For example, inexpensive sexual‑health drugs like sildenafil generate modest revenue per unit but retain very high gross margins, whereas newer, higher‑priced offerings dilute the overall margin profile. As the portfolio leans toward these lower‑margin products, the aggregate gross margin inevitably trends downward.

Investors listening to the analysis are reminded that margin compression signals limited upside for a compounder like HEMS. Without vertical integration, any improvement must come from operational efficiencies, pricing power, or a strategic shift back to higher‑margin core products. The discussion underscores the importance of monitoring product‑mix trends and gross‑margin trajectories when valuing telehealth and consumer‑health brands. Companies that can balance growth in new categories with preservation of profitable legacy lines are better positioned to sustain investor confidence and achieve long‑term profitability. Future earnings forecasts will therefore hinge on the company's ability to renegotiate supplier contracts or invest in its own manufacturing capabilities.